<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-137313</identifier>
<setSpec>1130-1406</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Candida norvegensis fungemia in a liver transplant recipient</dc:title>
<dc:description xml:lang="en">Background: The incidence of candidemia due to non-Candida albicans Candida species has been progressively increasing in recent years. The use of fluconazole as antifungal prophylaxis has been described as a risk factor for the development of infections by fluconazole resistant Candida strains. We report a case of Candida norvegensis bloodstream infection in a liver transplant recipient. Case report: A 61-year-old man, who received a third liver allograft and became worse with the onset of ischemic cholangiopathy and recurrent episodes of cholangitis, was admitted to our hospital due to the development of intra-abdominal abscesses. He received multiple antibiotic schemes, and after 3 months he was discharged, maintaining parenteral antibiotic at home. While he was on fluconazole prophylaxis, a breakthrough candidemia due to C. norvegensis occurred. In vitro susceptibilities of the isolate to several antifungal agents were as follows: amphotericin B MIC 0.5 mg/l, flucytosine 64 mg/l, fluconazole 64 mg/l, itraconazole 4 mg/l, voriconazole 0.75 mg/l, and caspofungin 0.047 mg/l. He was treated with anidulafungin with resolution of candidemia. Conclusions: The use of fluconazole for antifungal prophylaxis may lead to the emergence of fluconazoleresistant Candida infections, with C. norvegensis being a possible emerging pathogen in organ transplant recipients (AU)</dc:description>
<dc:creator>Pitart, Cristina</dc:creator>
<dc:creator>Moreno, Asunción</dc:creator>
<dc:creator>Almela, Manuel</dc:creator>
<dc:creator>Sanclemente, Gemma</dc:creator>
<dc:creator>Navasa, Miquel</dc:creator>
<dc:creator>Colmenero, Jordi</dc:creator>
<dc:creator>Hoyo, Irma</dc:creator>
<dc:creator>Marco, Francesc</dc:creator>
<dc:creator>Cervera, Carlos</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Antecedentes: En los últimos anos &#152; ha aumentado la incidencia de candidemia causada por especies del género Candida distintas de Candida albicans. Se ha descrito el uso de profilaxis antifúngica con fluconazol como factor de riesgo para el desarrollo de infecciones por cepas de Candida resistentes a este antifúngico. Se describe un caso de fungemia por Candida norvegensis en un receptor de un trasplante hepático. Caso clínico: Un varón de 61 anos, &#152; receptor de un tercer trasplante hepático que se complica con una colangiopatía isquémica y episodios de colangitis de repetición, ingresó en nuestro hospital por presentar abscesos intraabdominales. Recibió múltiples esquemas antibióticos y, tras 3 meses de ingreso, se dio de alta manteniendo un tratamiento antibiótico parenteral en domicilio. Mientras recibía pro- filaxis con fluconazol, desarrolló una candidemia de brecha por C. norvegensis. Los valores de CMI in vitro del aislamiento para algunos antifúngicos fueron los siguientes: anfotericina B 0,5 mg/l, flucitosina 64 mg/l, fluconazol 64 mg/l, itraconazol 4 mg/l, voriconazol 0,75 mg/l y caspofungina 0,047 mg/l. El paciente recibió tratamiento con anidulafungina, con resolución de la candidemia. Conclusiones: El uso de fluconazol como profilaxis antifúngica puede conllevar la aparición de infecciones por especies de Candida resistentes a este antifúngico, siendo C. norvegensis un posible patógeno emergente en pacientes receptores de un órgano sólido (AU)</dc:description>
<dc:source>Rev Iberoam Micol;32(2): 115-117, abr.-jun. 2015.</dc:source>
<dc:identifier>ibc-137313</dc:identifier>
<dc:title xml:lang="es">Fungemia por Candida norvegensis en un receptor de trasplante hepático</dc:title>
<dc:subject>^d24654^s22073</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d2207^s22052</dc:subject>
<dc:subject>^d53932^s22012</dc:subject>
<dc:subject>^d11622</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29476^s22020</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d2813^s22032</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:type>article</dc:type>
<dc:date>201506</dc:date>
</metadata>
</record>
</ibecs-document>
